Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study is currently recruiting participants.
Verified October 2013 by Duke University
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Anne Beaven, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT00978432
First received: September 15, 2009
Last updated: October 23, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)